Urine cell-free DNA as a promising biomarker for early detection of non-small cell lung cancer

被引:16
|
作者
Ren, Sai [1 ]
Ren, Xiao-Dong [1 ]
Guo, Li-Fang [1 ]
Qu, Xue-Mei [1 ]
Shang, Mei-Yun [1 ]
Dai, Xiao-Tian [2 ]
Huang, Qing [1 ]
机构
[1] Army Med Univ, Dept Lab Med, Daping Hosp, Chongqing 400042, Peoples R China
[2] Army Med Univ, Dept Pulmonol, Southwest Hosp, Chongqing 400038, Peoples R China
关键词
DNA integrity; LINE1 repeat sequences; non-small-cell lung cancer; quantitative real-time PCR; urine cell-free DNA; FREE CIRCULATING DNA; PLASMA DNA; POTENTIAL MARKER; BLOOD-PLASMA; INTEGRITY; METHYLATION; PROGRESSION; PREDICTION; DIAGNOSIS; TUMOR;
D O I
10.1002/jcla.23321
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background While blood-derived cell-free DNA has been shown to be a candidate biomarker able to provide diagnostic and prognostic insight in cancer patients, little is known regarding the potential application of urine cell-free DNA (ucfDNA) in diagnosis of cancer. Thus, the aim of this study was to investigate ucfDNA concentration and integrity index as potential biomarkers for early detection of non-small-cell lung cancer (NSCLC). Methods Urine samples were collected from 35 healthy controls and 55 NSCLC patients at various tumor node metastasis (TNM) stages. Two long interspersed nuclear element 1 (LINE1) fragments (LINE1-97 and 266 bp) were quantified via quantitative real-time PCR (qPCR). DNA integrity index was calculated as the ratio of LINE1-266/LINE-97. Results LINE1 fragments concentrations of ucfDNA (LINE1-97, 266 bp) were significantly higher in NSCLC patients with stage III/IV than in stage I/II and in healthy controls. The receiver operating characteristic (ROC) curves for discriminating patients with stage III/IV from healthy controls had areas under the curves (AUC) of 0.84 and 0.886, respectively. Moreover, ucfDNA integrity LINE1-266/97 was significantly higher in patients with stage III/IV than in stage I/II and in healthy controls. The AUC of ROC curve for discriminating patients with stage III/IV from healthy controls was 0.800. Furthermore, LINE1-266 fragment concentration was significantly higher in lymph node metastasis (LNM)-positive patients relative to LNM-negative patients. The ROC curve for discriminating LNM-positive from LNM-negative patients had an AUC of 0.822. Conclusion UcfDNA could serve as a promising biomarker for early detection of NSCLC.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] 5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer
    Ajmal, Zainub
    Shao, Jianming
    Olsen, Randall
    Kasparian, Saro
    He, Chuan
    Bernicker, Eric
    Li, Zejuan
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Cell-Free DNA From Nontumor Tissue in Patients With Non-small Cell Lung Cancer Response
    Roosan, Moom R.
    Mambetsariev, Isa
    Salgia, Ravi
    CHEST, 2021, 160 (04) : E371 - E372
  • [23] Molecular profiling of cell-free DNA and RNA in the blood of patients with non-small cell lung cancer
    Reese, Jordan
    Jackson, Leisa
    Mellert, Hestia S.
    Pestano, Gary
    CANCER RESEARCH, 2019, 79 (13)
  • [24] A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA
    Wei, Lirong
    Wu, Wangxi
    Han, Liming
    Yu, Weimo
    Du, Yuzhen
    ONCOLOGY LETTERS, 2018, 16 (04) : 4353 - 4360
  • [25] Nestin servers as a promising prognostic biomarker in non-small cell lung cancer
    Liu, Fang
    Zhang, Yuan
    Lu, Ming
    Wang, Cong
    Li, Qingbao
    Gao, Yongsheng
    Mu, Dianbin
    Cao, Yan
    Li, Miaomiao
    Meng, Xiangjiao
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (03): : 1392 - 1401
  • [26] Cell-Free Tumor DNA (ctDNA) Utility in Detection and Monitoring EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
    Agulnik, J.
    Kasymjanova, G.
    Papadakis, A.
    Small, D.
    Sakr, L.
    Pepe, C.
    Wang, H.
    Cohen, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1035 - S1035
  • [27] Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non-small cell lung cancer
    Alhanafy, A.
    El Shafei, S.
    Habib, M.
    Abdellatif, R.
    Haggag, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S17 - S18
  • [28] Use of cell free DNA as a prognostic biomarker in non-small cell lung cancer patients with bone metastasis
    Ye, Yongjian
    Luo, Zhihang
    Shi, Dejun
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2019, 34 (04): : 381 - 388
  • [29] Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer
    Liu, Bin
    Filho, Julio Ricarte
    Mallisetty, Apurva
    Villani, Cassandra
    Kottorou, Anastasia
    Rodgers, Kristen
    Chen, Chen
    Ito, Tomoaki
    Holmes, Kyla
    Gastala, Nicole
    Valyi-Nagy, Klara
    David, Odile
    Gaba, Ron C.
    Ascoli, Christian
    Pasquinelli, Mary
    Feldman, Lawrence E.
    Massad, Malek G.
    Wang, Tza-Huei
    Jusue-Torres, Ignacio
    Benedetti, Enrico
    Winn, Robert A.
    Brock, Malcolm V.
    Herman, James G.
    Hulbert, Alicia
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4339 - 4348
  • [30] Cell-free DNA as a predictive and prognostic marker in adjuvant-treated non-small cell lung cancer
    Azkona, E.
    Casas, R.
    Aurrekoetxea, J.
    De Elejoste Echebarria, I.
    Fernandez, M.
    Sagarduy, J. Azcuna
    Garcia, L.
    Saiz, M.
    Gallastegi, B. Ortega
    Calvo, B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S93 - S93